Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

Rhea-AI Summary

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) will release its fourth quarter and full year 2022 financial results on March 13, 2023, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call toll-free at 800-445-7795 (U.S.) or 785-424-1789 (International). A replay will be available for two weeks, and the webcast will be archived for 30 days on the company's website.

Eagle specializes in developing innovative medicines and has a portfolio of commercialized products including vasopressin and BENDEKA®. The company focuses on addressing critical care and oncology needs.

Positive

• Eagle will provide Q4 and full year 2022 financial results, which may include key performance metrics.
• The upcoming conference call presents an opportunity for investors to gain insights directly from the CEO and CFO.

Negative

• None.

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.

Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date:	Monday, March 13, 2023
Time:	8:30 a.m. ET
Toll free (U.S.)	800-445-7795
International	785-424-1789
Webcast (live and replay)	www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for two weeks after the call's completion by dialing 800-839-4199 (U.S.) or 402-220-2989 (International) and entering conference call ID EGRXQ422. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include vasopressin, PEMFEXY^®, RYANODEX^®, BENDEKA^®, BELRAPZO^®, TREAKISYM^® (Japan), and BYFAVO^® and BARHEMSYS^® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

Contact:
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When will Eagle Pharmaceuticals announce its Q4 2022 financial results?

Eagle Pharmaceuticals will announce its Q4 2022 financial results on March 13, 2023.

What time is the Eagle Pharmaceuticals conference call regarding Q4 results?

The conference call will take place at 8:30 a.m. ET on March 13, 2023.

How can I access the replay of the Eagle Pharmaceuticals conference call?

The replay can be accessed by dialing 800-839-4199 (U.S.) or 402-220-2989 (International) using conference call ID EGRXQ422.

Where can I find the webcast for the Eagle Pharmaceuticals conference call?

The webcast will be available on Eagle Pharmaceuticals' website under the Investor Relations section.

What are some of the products in Eagle Pharmaceuticals' portfolio?

Eagle's portfolio includes vasopressin, PEMFEXY®, RYANODEX®, and BENDEKA®.